XML 30 R14.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2025
SEGMENT INFORMATION  
SEGMENT INFORMATION

NOTE 8 – SEGMENT INFORMATION

a.The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.
b.Segment information:

Nine Months Ended September 30, 

Three Months Ended September 30, 

(U.S. dollars in thousands)

2025

2024

2025

2024

Revenues from customers

$

43,622

$

35,181

$

17,851

$

17,959

Less:

Employee salaries and related expenses

16,502

15,091

5,853

4,734

Sub-contractors expense

9,348

6,413

1,886

1,649

Interest expense

1,021

260

Interest income

(817)

(970)

(289)

(212)

Depreciation

1,078

970

372

329

Other segment expenses*

18,343

15,818

7,790

7,356

Income (loss) before taxes on income

(832)

(3,162)

2,239

3,843

Taxes on income (tax benefit)

268

400

(116)

607

Segment net income (loss)

$

(1,100)

$

(3,562)

$

2,355

$

3,236

* Other expenses included in net income includes raw materials, rent and utilities and others.

c.The following table summarizes the Company’s disaggregation of revenues:

Nine Months Ended September 30, 

Three Months Ended September 30, 

(U.S. dollars in thousands)

2025

2024

    

2025

2024

Gaucher disease:

 

Pfizer (Ireland)

$

15,431

$

11,431

$

2,805

$

3,430

Fiocruz (Brazil)

$

9,121

$

9,314

$

6,105

$

2,048

Fabry disease:

Chiesi (Italy)

$

18,556

$

14,075

$

8,763

$

12,361

Total revenues from selling goods

$

43,108

$

34,820

$

17,673

$

17,839

Revenues from license and R&D services

$

514

$

361

$

178

$

120

d.Long lived assets are located in Israel.